Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06827990 · ClinicalTrials.gov registry record · NA

GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections

A NA study of Aortic Dissection, sponsored by W.L.Gore & Associates.

Recruiting
Registry status
NA
Development phase
112
Enrollment target
13
Study locations

NCT06827990 is a NA study of Aortic Dissection that is actively recruiting participants, run by W.L.Gore & Associates. The registered enrollment target is 112 participants, below the 654-participant average among 11 other Aortic Dissection trials with a reported enrollment target (83% lower). The trial reports 13 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06827990, a NA study of Aortic Dissection, is actively recruiting participants, sponsored by W.L.Gore & Associates.

RECRUITING
Registry status
NA
Development phase
112 participants
Enrollment target
13
Study locations

Study Summary

To assess the safety and effectiveness of the ASG device in the treatment of de novo Type A aortic dissections.

Conditions Studied

Interventions

  • DEVICE GORE® Ascending Stent Graft (ASG device)

Study Locations (13)

Ohio

  • Cleveland Clinic - Cleveland
  • Ohio Health Research Institute - Columbus

Texas

  • The Methodist Hospital Houston - Houston
  • Baylor Research Institute - Plano

Alabama

  • University of Alabama at Birmingham - Birmingham

Florida

  • University of Florida - Gainesville

Georgia

  • Emory University School of Medicine - Atlanta

Illinois

  • Northwestern Medicine - Chicago

Indiana

  • Indiana University - Indianapolis

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 112 participants
Start Date 2025-09-22
Est. Completion 2031-09-01
Phase NA

Sponsor

W.L.Gore & Associates

53 total trials

What the Registry Record Tells You About NCT06827990

The ClinicalTrials.gov registry entry for NCT06827990 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 654-participant average among 11 other Aortic Dissection trials with a reported enrollment target (83% lower). The listed sponsor is W.L.Gore & Associates, which has 53 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Aortic Dissection appearing as the primary indexed condition, and to 1 intervention - of which GORE® Ascending Stent Graft (ASG device) is the first listed.

NCT06827990 reports 13 study locations spanning 11 distinct geographic areas - top geographies include Ohio, Texas, Alabama.

Frequently Asked Questions

What is clinical trial NCT06827990 about?

NCT06827990 is a clinical study titled "GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections". To assess the safety and effectiveness of the ASG device in the treatment of de novo Type A aortic dissections.

What is the current status of trial NCT06827990?

This trial is currently recruiting. It is a NA study. The enrollment target is 112 participants. The study started on 2025-09-22. Estimated completion is 2031-09-01.

What conditions does trial NCT06827990 study?

This clinical trial studies the following conditions: Aortic Dissection.

What interventions are being tested in trial NCT06827990?

The interventions under investigation include: GORE® Ascending Stent Graft (ASG device) (DEVICE).

Who is sponsoring clinical trial NCT06827990?

This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06827990 being conducted?

This trial has 13 study locations across Alabama, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aortic Dissection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.